MINOXIDIL FOAM 5% (WOMENS)

MINOXIDIL FOAM 5% (WOMENS) was reported 33385 times

MINOXIDIL FOAM 5% (WOMENS) is most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 VASCULAR ANASTOMOTIC HAEMORRHAGE 19 0.6333
1 APPLICATION SITE PLAQUE 6 0.2609
2 APPLICATION SITE DRYNESS 746 0.2195
3 APPLICATION SITE ACNE 106 0.2163
4 DANDRUFF 475 0.2145
5 PERINEAL CYST 14 0.1918
6 APPLICATION SITE ULCER 134 0.1893
7 VENA CAVA INJURY 17 0.1848
8 HYPERTRICHOSIS 286 0.1542
9 APPLICATION SITE PAPULES 160 0.1508
10 PANCREATIC CYSTADENOMA 7 0.1458
11 INJECTION SITE ALOPECIA 6 0.1364
12 APPLICATION SITE EXFOLIATION 544 0.1319
13 APPLICATION SITE PRURITUS 2580 0.1136
14 RENAL CYST HAEMORRHAGE 24 0.1062
15 ANAL CYST 6 0.1034
16 APPLICATION SITE IRRITATION 1250 0.1004
17 APPLICATION SITE SCAB 212 0.0981
18 APPLICATION SITE FOLLICULITIS 7 0.0972
19 ADVERSE DRUG REACTION 8609 0.0958
20 HAIR INJURY 26 0.0875
21 APPLICATION SITE ECZEMA 6 0.0690
22 APPLICATION SITE FISSURE 6 0.0667
23 LICHEN PLANOPILARIS 7 0.0593
24 VASCULAR COMPRESSION 18 0.0570
25 GENITAL DISORDER 7 0.0522
26 APPLICATION SITE PAIN 1109 0.0503
27 ABDOMINAL WALL HAEMORRHAGE 13 0.0498
28 INTRADUCTAL PAPILLARY MUCINOUS NEOPLASM 15 0.0495
29 APPLICATION SITE WOUND 8 0.0485
30 APPLICATION SITE INJURY 9 0.0474
31 CENTRAL SEROUS CHORIORETINOPATHY 32 0.0469
32 APPLICATION SITE PARAESTHESIA 60 0.0460
33 APPLICATION SITE INFLAMMATION 59 0.0426
34 APPLICATION SITE PUSTULES 15 0.0411
35 PRODUCT ADMINISTERED AT INAPPROPRIATE SITE 674 0.0367
36 APPLICATION SITE NODULE 5 0.0365
37 APPLICATION SITE DISCOMFORT 64 0.0356
38 POST 5-ALPHA-REDUCTASE INHIBITOR SYNDROME 10 0.0352
39 MIXED ANXIETY AND DEPRESSIVE DISORDER 13 0.0351
40 BLOOD 25-HYDROXYCHOLECALCIFEROL DECREASED 10 0.0345
41 APPLICATION SITE HYPOAESTHESIA 8 0.0342
42 GLOMERULONEPHRITIS ACUTE 7 0.0340
43 APPLICATION SITE INFECTION 17 0.0334
44 APPLICATION SITE DISCHARGE 37 0.0321
45 APPLICATION SITE RASH 434 0.0315
46 DELAYED GRAFT FUNCTION 22 0.0309
47 HAIR TEXTURE ABNORMAL 385 0.0288
48 HYPERPARATHYROIDISM SECONDARY 71 0.0283
49 ANDROGENETIC ALOPECIA 8 0.0282
50 SKIN FIBROSIS 13 0.0269
51 PAINFUL EJACULATION 6 0.0265
52 EXPOSURE VIA EYE CONTACT 11 0.0261
53 MYOCARDIAL NECROSIS 6 0.0258
54 ALOPECIA UNIVERSALIS 7 0.0239
55 INTERVERTEBRAL DISC SPACE NARROWING 19 0.0236
56 APPLICATION SITE HYPERSENSITIVITY 28 0.0230
57 APPLICATION SITE ERYTHEMA 603 0.0230
58 PENILE SIZE REDUCED 21 0.0221
59 CHRONIC KIDNEY DISEASE-MINERAL AND BONE DISORDER 23 0.0217
60 CAROTID ARTERIOSCLEROSIS 22 0.0213
61 TRICHORRHEXIS 59 0.0211
62 HAIR COLOUR CHANGES 262 0.0210
63 AORTIC DILATATION 23 0.0207
64 PNEUMONIA HAEMOPHILUS 10 0.0206
65 NEPHROGENIC ANAEMIA 92 0.0198
66 APPLICATION SITE HAEMORRHAGE 54 0.0198
67 APPLICATION SITE BURN 93 0.0189
68 SCROTAL OEDEMA 13 0.0183
69 TESTICULAR PAIN 58 0.0183
70 SEBORRHOEA 67 0.0182
71 RECTAL PROLAPSE 22 0.0182
72 HAIR GROWTH ABNORMAL 126 0.0182
73 RENAL ARTERY STENOSIS 25 0.0181
74 APPLICATION SITE VESICLES 116 0.0179
75 PRODUCT LABEL ON WRONG PRODUCT 7 0.0177
76 PLEUROPERICARDITIS 7 0.0170
77 MUSCULAR DYSTROPHY 7 0.0161
78 TESTICULAR ATROPHY 14 0.0161
79 EAR SWELLING 34 0.0160
80 PRODUCT MONITORING ERROR 23 0.0159
81 APPLICATION SITE WARMTH 20 0.0157
82 BLADDER TRANSITIONAL CELL CARCINOMA 22 0.0154
83 CHEMICAL BURN 17 0.0147
84 LIBIDO DISORDER 19 0.0146
85 ARTERIOVENOUS FISTULA 7 0.0142
86 NEPHROGENIC SYSTEMIC FIBROSIS 43 0.0142
87 SEMEN VOLUME DECREASED 14 0.0140
88 APPLICATION SITE DERMATITIS 13 0.0139
89 DRUG ADMINISTERED AT INAPPROPRIATE SITE 146 0.0138
90 MEIBOMIAN GLAND DYSFUNCTION 6 0.0132
91 APPLICATION SITE REACTION 83 0.0118
92 LAZINESS 20 0.0117
93 SKIN WRINKLING 31 0.0114
94 END STAGE RENAL DISEASE 205 0.0112
95 JOINT CONTRACTURE 12 0.0112
96 SEBORRHOEIC DERMATITIS 18 0.0109
97 CARDIAC HYPERTROPHY 12 0.0108
98 PRODUCT FORMULATION ISSUE 70 0.0106
99 INTELLECTUAL DISABILITY 16 0.0105
100 SKIN TEXTURE ABNORMAL 10 0.0104
101 BLOOD OESTROGEN INCREASED 6 0.0102
102 COMPLICATIONS OF TRANSPLANTED KIDNEY 23 0.0101
103 INGROWN HAIR 7 0.0101
104 HYPERTENSIVE ENCEPHALOPATHY 6 0.0101
105 EXPIRED PRODUCT ADMINISTERED 336 0.0101
106 ACTINIC KERATOSIS 26 0.0100
107 PENIS DISORDER 24 0.0097
108 LOSS OF LIBIDO 87 0.0097
109 SKIN INDURATION 20 0.0096
110 SEXUAL DYSFUNCTION 113 0.0096
111 DARK CIRCLES UNDER EYES 14 0.0095
112 EXTREMITY CONTRACTURE 6 0.0094
113 LEFT VENTRICULAR HYPERTROPHY 40 0.0093
114 VANISHING BILE DUCT SYNDROME 10 0.0090
115 MEAN CELL VOLUME INCREASED 23 0.0090
116 AORTIC ARTERIOSCLEROSIS 23 0.0089
117 APPLICATION SITE DISCOLOURATION 36 0.0089
118 GENITAL HYPOAESTHESIA 9 0.0088
119 COLLAGEN DISORDER 5 0.0087
120 SKIN SENSITISATION 9 0.0087
121 HEPATOSPLENOMEGALY 22 0.0086
122 HYPERTENSIVE EMERGENCY 10 0.0085
123 ERECTILE DYSFUNCTION 218 0.0085
124 AURICULAR SWELLING 5 0.0083
125 MALIGNANT HYPERTENSION 7 0.0081
126 RENAL TRANSPLANT FAILURE 8 0.0081
127 APPLICATION SITE SWELLING 39 0.0078
128 HYPERPARATHYROIDISM 15 0.0073
129 APPLICATION SITE SCAR 9 0.0072
130 SWELLING OF EYELID 45 0.0072
131 DRUG ADMINISTERED IN WRONG DEVICE 7 0.0072
132 CARDIAC TAMPONADE 34 0.0071
133 CHORIORETINOPATHY 10 0.0070
134 APPLICATION SITE EROSION 9 0.0070
135 PERIORBITAL SWELLING 38 0.0067
136 REBOUND ACID HYPERSECRETION 20 0.0066
137 EJACULATION FAILURE 13 0.0065
138 SKIN TEST POSITIVE 6 0.0064
139 SKIN HYPERTROPHY 18 0.0064
140 NIPPLE PAIN 13 0.0064
141 ALOPECIA AREATA 11 0.0063
142 PERICARDIAL EFFUSION 142 0.0061
143 THERAPEUTIC PRODUCT EFFECT DELAYED 27 0.0059
144 AORTIC VALVE INCOMPETENCE 25 0.0059
145 APPLICATION SITE URTICARIA 13 0.0058
146 HYPERTENSIVE NEPHROPATHY 6 0.0056
147 SPINAL STENOSIS 23 0.0056
148 ALLERGIC REACTION TO EXCIPIENT 11 0.0055
149 SKIN TIGHTNESS 25 0.0053
150 OCULAR HYPERTENSION 10 0.0051
151 DIVERTICULUM INTESTINAL 22 0.0050
152 BENIGN PROSTATIC HYPERPLASIA 25 0.0048
153 PERIORBITAL OEDEMA 25 0.0048
154 DRUG INEFFECTIVE 6284 0.0048
155 MENTAL FATIGUE 7 0.0047
156 ALOPECIA 907 0.0046
157 ELECTROCARDIOGRAM ST SEGMENT DEPRESSION 10 0.0045
158 HIRSUTISM 6 0.0045
159 PAPULE 31 0.0044
160 ACTIVATED PARTIAL THROMBOPLASTIN TIME PROLONGED 22 0.0043
161 INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION 781 0.0043
162 EPIDIDYMITIS 5 0.0043
163 ALLODYNIA 5 0.0043
164 EJACULATION DISORDER 12 0.0042
165 FIBROSIS 13 0.0042
166 CHRONIC KIDNEY DISEASE 316 0.0042
167 RENAL TRANSPLANT 15 0.0041
168 BICYTOPENIA 8 0.0041
169 DISTRIBUTIVE SHOCK 9 0.0040
170 KIDNEY TRANSPLANT REJECTION 19 0.0040
171 LARGE INTESTINE POLYP 27 0.0039
172 OLIGURIA 24 0.0039
173 ESSENTIAL HYPERTENSION 7 0.0038
174 SQUAMOUS CELL CARCINOMA OF SKIN 23 0.0038
175 BLOOD PARATHYROID HORMONE INCREASED 11 0.0038
176 ACROCHORDON 5 0.0038
177 EAR PRURITUS 13 0.0037
178 INAPPROPRIATE SCHEDULE OF DRUG ADMINISTRATION 263 0.0037
179 ATRIOVENTRICULAR BLOCK FIRST DEGREE 16 0.0037
180 ELECTROCARDIOGRAM T WAVE INVERSION 8 0.0036
181 RENAL CYST 28 0.0035
182 RENAL FAILURE CHRONIC 27 0.0035
183 HYPERTENSIVE CRISIS 39 0.0035
184 METHAEMOGLOBINAEMIA 8 0.0035
185 BRAIN FOG 54 0.0034
186 BLOOD TESTOSTERONE DECREASED 23 0.0034
187 DERMATITIS CONTACT 38 0.0033
188 SCAB 38 0.0033
189 HYPERSENSITIVITY 613 0.0033
190 BLOOD PHOSPHORUS INCREASED 9 0.0033
191 GLOMERULONEPHRITIS 8 0.0033
192 DERMAL CYST 8 0.0033
193 HYPERPHOSPHATAEMIA 7 0.0033
194 AZOTAEMIA 13 0.0033
195 DRUG EFFECT LESS THAN EXPECTED 48 0.0032
196 VENTRICULAR HYPERTROPHY 8 0.0032
197 ARTERIOSCLEROSIS 30 0.0032
198 SPINAL OSTEOARTHRITIS 28 0.0032
199 SWELLING FACE 201 0.0031
200 ANGIONEUROTIC OEDEMA 8 0.0030
201 BLOOD POTASSIUM INCREASED 48 0.0030
202 SUSPECTED OFF LABEL USE 13 0.0029
203 NAIL DISCOLOURATION 11 0.0028
204 SKIN IRRITATION 128 0.0028
205 PORTAL VEIN THROMBOSIS 9 0.0028
206 UNDERDOSE 200 0.0027
207 RENAL INJURY 81 0.0027
208 PALPITATIONS 319 0.0027
209 FEAR OF DEATH 6 0.0027
210 RESTLESS LEGS SYNDROME 48 0.0026
211 EYE SWELLING 98 0.0026
212 ATRIOVENTRICULAR BLOCK 20 0.0026
213 FLUID OVERLOAD 37 0.0025
214 SKIN SWELLING 22 0.0025
215 SKIN REACTION 35 0.0025
216 DEVICE RELATED SEPSIS 5 0.0025
217 WRONG DRUG ADMINISTERED 22 0.0025
218 ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY POSITIVE VASCULITIS 6 0.0024
219 CONDITION AGGRAVATED 736 0.0024
220 HEART RATE INCREASED 237 0.0024
221 SKIN EXFOLIATION 201 0.0024
222 ABSCESS INTESTINAL 5 0.0023
223 ACCIDENTAL EXPOSURE TO PRODUCT 226 0.0022
224 HAIR DISORDER 18 0.0022
225 NEURODERMATITIS 8 0.0021
226 DISCOURAGEMENT 5 0.0021
227 THROMBOSIS IN DEVICE 7 0.0021
228 RENAL FAILURE 282 0.0021
229 THERAPEUTIC PRODUCT EFFECT DECREASED 95 0.0021
230 HAEMORRHOIDS 41 0.0021
231 RASH PAPULAR 47 0.0021
232 PRODUCT ADMINISTRATION ERROR 42 0.0021
233 DIALYSIS 29 0.0020
234 HAEMODIALYSIS 17 0.0020
235 DRUG INEFFECTIVE FOR UNAPPROVED INDICATION 111 0.0020
236 URINE ANALYSIS ABNORMAL 6 0.0020
237 FOLLICULITIS 21 0.0020
238 HEART RATE IRREGULAR 45 0.0020
239 SKIN HYPERPIGMENTATION 17 0.0020
240 CHEMICAL BURN OF SKIN 5 0.0020
241 EXPOSURE VIA SKIN CONTACT 51 0.0020
242 BLOOD PRESSURE FLUCTUATION 47 0.0020
243 BRAIN NATRIURETIC PEPTIDE INCREASED 6 0.0019
244 VITREOUS FLOATERS 19 0.0019
245 ROSACEA 9 0.0019
246 SUICIDAL BEHAVIOUR 8 0.0019
247 BASAL CELL CARCINOMA 30 0.0019
248 LABELLED DRUG-DRUG INTERACTION MEDICATION ERROR 17 0.0019
249 WRONG TECHNIQUE IN PRODUCT USAGE PROCESS 387 0.0019
250 SENSITIVE SKIN 14 0.0019
251 INCORRECT DOSE ADMINISTERED 431 0.0019
252 PULMONARY HYPERTENSION 39 0.0019
253 VITAMIN D DECREASED 16 0.0019
254 PRESYNCOPE 45 0.0018
255 ANORGASMIA 5 0.0018
256 EYE IRRITATION 106 0.0018
257 BREAST ENLARGEMENT 6 0.0018
258 BLOOD PRESSURE INADEQUATELY CONTROLLED 11 0.0018
259 MELANOCYTIC NAEVUS 8 0.0018
260 NEPHROPATHY 17 0.0018
261 VENOUS THROMBOSIS 7 0.0018
262 GENERALISED OEDEMA 22 0.0018
263 DIABETIC RETINOPATHY 6 0.0018
264 HEADACHE 1103 0.0018
265 SOCIAL AVOIDANT BEHAVIOUR 10 0.0017
266 ANHEDONIA 45 0.0017
267 UMBILICAL HERNIA 8 0.0017
268 AUTONOMIC NERVOUS SYSTEM IMBALANCE 5 0.0017
269 ACUTE CORONARY SYNDROME 14 0.0017
270 SKIN WEEPING 6 0.0017
271 OFF LABEL USE 1459 0.0017
272 PRODUCT ADMINISTRATION INTERRUPTED 13 0.0017
273 ENTEROCOCCAL INFECTION 8 0.0017
274 AFFECTIVE DISORDER 13 0.0017
275 PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE 10 0.0016
276 FACIAL PARALYSIS 14 0.0016
277 HORMONE LEVEL ABNORMAL 8 0.0016
278 BREAST MASS 11 0.0016
279 DEAFNESS UNILATERAL 9 0.0016
280 PROTEINURIA 31 0.0016
281 TEARFULNESS 7 0.0016
282 ACNE 123 0.0016
283 DIASTOLIC DYSFUNCTION 5 0.0016
284 CARDIAC FAILURE CONGESTIVE 130 0.0016
285 ACCIDENTAL EXPOSURE TO PRODUCT BY CHILD 11 0.0016
286 DIABETIC NEUROPATHY 8 0.0016
287 HEPATIC STEATOSIS 30 0.0016
288 CHEST PAIN 298 0.0016
289 NEPHROTIC SYNDROME 11 0.0016
290 ADVERSE REACTION 21 0.0016
291 TROPONIN INCREASED 12 0.0016
292 DERMATITIS 33 0.0016
293 DRY SKIN 210 0.0016
294 CONJUNCTIVAL HAEMORRHAGE 6 0.0016
295 JOINT RANGE OF MOTION DECREASED 21 0.0016
296 RASH 668 0.0015
297 ACUTE KIDNEY INJURY 234 0.0015
298 ACUTE MYOCARDIAL INFARCTION 45 0.0015
299 SKIN ODOUR ABNORMAL 6 0.0015
300 PNEUMONIA FUNGAL 6 0.0015
301 ECONOMIC PROBLEM 23 0.0015
302 DERMATITIS ALLERGIC 19 0.0015
303 HYPERPHAGIA 6 0.0015
304 SKIN PAPILLOMA 6 0.0015
305 PERITONITIS BACTERIAL 15 0.0015
306 SKIN DISORDER 49 0.0015
307 ANGINA PECTORIS 42 0.0015
308 APLASIA PURE RED CELL 5 0.0015
309 EPSTEIN-BARR VIRUS INFECTION 9 0.0014
310 INCORRECT PRODUCT ADMINISTRATION DURATION 31 0.0014
311 THERMAL BURN 10 0.0014
312 CAROTID ARTERY OCCLUSION 5 0.0014
313 DYSPHEMIA 6 0.0014
314 INITIAL INSOMNIA 14 0.0014
315 FACE OEDEMA 23 0.0014
316 HAEMATOCRIT DECREASED 27 0.0014
317 PERIPHERAL VASCULAR DISORDER 7 0.0014
318 ARTERIOSCLEROSIS CORONARY ARTERY 9 0.0014
319 BLOOD CREATINE INCREASED 6 0.0014
320 HYPERTENSION 287 0.0014
321 OEDEMA PERIPHERAL 165 0.0014
322 PANIC ATTACK 49 0.0013
323 POLYURIA 11 0.0013
324 IRON DEFICIENCY 6 0.0013
325 WRONG PRODUCT ADMINISTERED 9 0.0013
326 BODY TEMPERATURE DECREASED 13 0.0013
327 PULMONARY OEDEMA 59 0.0013
328 PRODUCT USE ISSUE 247 0.0013
329 HYPERKALAEMIA 46 0.0013
330 BLOOD PRESSURE ABNORMAL 26 0.0013
331 FEAR 35 0.0013
332 PLEURAL EFFUSION 79 0.0013
333 PRODUCT RESIDUE PRESENT 7 0.0013
334 SLEEP DISORDER DUE TO A GENERAL MEDICAL CONDITION 22 0.0013
335 FORMICATION 9 0.0013
336 EYELID OEDEMA 15 0.0013
337 SCAR 22 0.0013
338 DIZZINESS 640 0.0013
339 ASTHENOPIA 7 0.0013
340 SKIN DISCOLOURATION 58 0.0013
341 DEPRESSION 284 0.0012
342 PANIC REACTION 9 0.0012
343 INCORRECT DRUG ADMINISTRATION DURATION 35 0.0012
344 RASH VESICULAR 6 0.0012
345 TUBULOINTERSTITIAL NEPHRITIS 23 0.0012
346 INCORRECT ROUTE OF PRODUCT ADMINISTRATION 21 0.0012
347 RED BLOOD CELL COUNT DECREASED 35 0.0012
348 RENAL TUBULAR NECROSIS 12 0.0012
349 CARDIOMEGALY 15 0.0012
350 PSYCHIATRIC SYMPTOM 9 0.0012
351 OEDEMA 66 0.0012
352 SKIN ATROPHY 7 0.0012
353 TACHYCARDIA 108 0.0012
354 HYPERVOLAEMIA 6 0.0012
355 ABDOMINAL TENDERNESS 6 0.0012
356 ORTHOSTATIC HYPOTENSION 21 0.0012
357 ECZEMA 63 0.0012
358 RESTLESSNESS 44 0.0012
359 CONGESTIVE CARDIOMYOPATHY 5 0.0012
360 BREAST TENDERNESS 9 0.0012
361 METABOLIC ACIDOSIS 38 0.0012
362 SKIN PLAQUE 10 0.0012
363 GLUCOSE TOLERANCE IMPAIRED 7 0.0012
364 IMPAIRED QUALITY OF LIFE 17 0.0012
365 BLOOD PRESSURE INCREASED 180 0.0012
366 WEIGHT INCREASED 263 0.0012
367 HYPERLIPIDAEMIA 14 0.0012
368 ENDOCARDITIS 6 0.0012
369 EAR DISCOMFORT 12 0.0012
370 VERTIGO 71 0.0012
371 TYPE 1 DIABETES MELLITUS 7 0.0012
372 SKIN INFECTION 13 0.0012
373 OCULAR DISCOMFORT 13 0.0012
374 EYE INFLAMMATION 11 0.0012
375 MYOCARDIAL ISCHAEMIA 13 0.0011
376 FLUID RETENTION 58 0.0011
377 GLOMERULAR FILTRATION RATE DECREASED 14 0.0011
378 GROIN PAIN 10 0.0011
379 SKIN BURNING SENSATION 81 0.0011
380 ATRIAL FLUTTER 9 0.0011
381 THINKING ABNORMAL 21 0.0011
382 SINUS TACHYCARDIA 16 0.0011
383 PERIPHERAL SWELLING 173 0.0011
384 ARRHYTHMIA 53 0.0011
385 MENTAL IMPAIRMENT 27 0.0011
386 SWELLING 104 0.0011
387 PHOTOPSIA 7 0.0011
388 ANXIETY 315 0.0011
389 CEREBRAL INFARCTION 27 0.0011
390 PRURITUS 424 0.0011
391 SLEEP APNOEA SYNDROME 21 0.0011
392 NONSPECIFIC REACTION 6 0.0011
393 ORAL DISORDER 8 0.0011
394 HAEMOGLOBIN ABNORMAL 7 0.0011
395 PERICARDITIS 18 0.0011
396 ACUTE PULMONARY OEDEMA 6 0.0011
397 GASTROOESOPHAGEAL REFLUX DISEASE 86 0.0011
398 PRODUCT PREPARATION ISSUE 7 0.0011
399 PHOTOPHOBIA 20 0.0011
400 MOOD ALTERED 29 0.0011
401 MIGRAINE 101 0.0011
402 BLOOD CREATININE INCREASED 69 0.0011
403 CHEST DISCOMFORT 108 0.0011
404 NEUROLOGICAL SYMPTOM 6 0.0010
405 PRODUCT PRESCRIBING ERROR 25 0.0010
406 BOWEL MOVEMENT IRREGULARITY 8 0.0010
407 CARDIAC MURMUR 9 0.0010
408 DEVICE RELATED INFECTION 16 0.0010
409 ATRIAL FIBRILLATION 101 0.0010
410 GYNAECOMASTIA 32 0.0010
411 BLISTER 58 0.0010
412 STRESS CARDIOMYOPATHY 6 0.0010
413 URINE OUTPUT DECREASED 9 0.0010
414 CARDIO-RESPIRATORY ARREST 43 0.0010
415 VITAMIN D DEFICIENCY 10 0.0010
416 HAEMORRHAGIC STROKE 8 0.0010
417 CORONARY ARTERY DISEASE 31 0.0010
418 PRODUCT PREPARATION ERROR 21 0.0010
419 DECREASED ACTIVITY 11 0.0010
420 ELECTROCARDIOGRAM ABNORMAL 8 0.0010
421 INTRAOCULAR PRESSURE INCREASED 13 0.0010
422 BLOOD UREA INCREASED 17 0.0010
423 ACCIDENTAL OVERDOSE 37 0.0010
424 FACIAL PAIN 9 0.0010
425 VISION BLURRED 138 0.0010
426 GLYCOSYLATED HAEMOGLOBIN INCREASED 25 0.0010
427 MUSCLE DISORDER 8 0.0010
428 BURNING SENSATION 69 0.0010
429 POST PROCEDURAL INFECTION 8 0.0010
430 DEPRESSED MOOD 52 0.0010
431 MITRAL VALVE INCOMPETENCE 11 0.0010
432 PIGMENTATION DISORDER 6 0.0010
433 SKIN ULCER 25 0.0010
434 GASTROENTERITIS 14 0.0010
435 HYPOTENSION 192 0.0010
436 IMPAIRED GASTRIC EMPTYING 13 0.0010
437 GOUT 17 0.0009
438 FOREIGN BODY SENSATION IN EYES 6 0.0009
439 INTENTIONAL PRODUCT USE ISSUE 82 0.0009
440 ERYTHEMA 192 0.0009
441 BLOOD PRESSURE DECREASED 62 0.0009
442 DRUG EFFECT DECREASED 50 0.0009
443 CARDIAC FLUTTER 6 0.0009
444 URTICARIA 155 0.0009
445 PRURITUS GENERALISED 20 0.0009
446 CONTRAINDICATED PRODUCT ADMINISTERED 28 0.0009
447 TENDON PAIN 7 0.0009
448 TARDIVE DYSKINESIA 26 0.0009
449 REFUSAL OF TREATMENT BY PATIENT 6 0.0009
450 ASPIRATION 10 0.0009
451 LUNG INFILTRATION 8 0.0009
452 APPETITE DISORDER 6 0.0009
453 BLOOD SODIUM DECREASED 17 0.0009
454 PELVIC FRACTURE 7 0.0009
455 ATRIOVENTRICULAR BLOCK COMPLETE 6 0.0009
456 SUICIDAL IDEATION 82 0.0009
457 HYPOAESTHESIA 134 0.0009
458 TINNITUS 41 0.0009
459 POSTOPERATIVE WOUND INFECTION 6 0.0009
460 DRUG EFFECTIVE FOR UNAPPROVED INDICATION 26 0.0009
461 EYELID PTOSIS 9 0.0009
462 PARAESTHESIA 139 0.0009
463 NASAL DISCOMFORT 7 0.0009
464 SLUGGISHNESS 9 0.0009
465 TRICUSPID VALVE INCOMPETENCE 7 0.0009
466 RENAL IMPAIRMENT 74 0.0009
467 CARDIOMYOPATHY 13 0.0009
468 DYSPNOEA EXERTIONAL 33 0.0009
469 IMMUNODEFICIENCY 13 0.0009
470 BLOOD PRESSURE SYSTOLIC INCREASED 17 0.0009
471 CORONARY ARTERY BYPASS 5 0.0009
472 PERITONITIS 18 0.0009
473 NIGHT SWEATS 28 0.0009
474 EYE DISCHARGE 9 0.0009
475 BLOOD URIC ACID INCREASED 5 0.0009
476 MADAROSIS 10 0.0009
477 POOR QUALITY PRODUCT ADMINISTERED 9 0.0009
478 PHOTOSENSITIVITY REACTION 14 0.0008
479 MEDICATION ERROR 47 0.0008
480 BREAST PAIN 9 0.0008
481 TENDONITIS 13 0.0008
482 FEELING JITTERY 16 0.0008
483 DRUG ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE 6 0.0008
484 CARDIAC DISORDER 78 0.0008
485 POST PROCEDURAL COMPLICATION 16 0.0008
486 MENINGIOMA 13 0.0008
487 SINUS BRADYCARDIA 8 0.0008
488 LACRIMATION INCREASED 25 0.0008
489 RENAL FAILURE ACUTE 35 0.0008
490 PERITONEAL DIALYSIS COMPLICATION 6 0.0008
491 EAR PAIN 16 0.0008
492 APATHY 12 0.0008
493 QUALITY OF LIFE DECREASED 11 0.0008
494 ASCITES 24 0.0008
495 MOOD SWINGS 26 0.0008
496 THERAPEUTIC PRODUCT EFFECT INCOMPLETE 58 0.0008
497 EYE PAIN 46 0.0008
498 DYSURIA 30 0.0008
499 LIP SWELLING 27 0.0008
500 BRADYCARDIA 43 0.0008
501 NERVE INJURY 9 0.0008
502 HAEMOGLOBIN DECREASED 83 0.0008
503 EYE PRURITUS 27 0.0008
504 OCULAR HYPERAEMIA 38 0.0008
505 SWOLLEN TONGUE 25 0.0008
506 RETCHING 17 0.0008
507 PAROSMIA 6 0.0008
508 MENTAL STATUS CHANGES 22 0.0008
509 NO ADVERSE EVENT 142 0.0008
510 NASAL CONGESTION 46 0.0008
511 SPEECH DISORDER 41 0.0008
512 DRY EYE 39 0.0008
513 MYOSITIS 7 0.0008
514 HAEMOLYSIS 6 0.0008
515 CONCUSSION 6 0.0008
516 VENTRICULAR EXTRASYSTOLES 8 0.0008
517 DIPLOPIA 20 0.0008
518 ANGINA UNSTABLE 5 0.0008
519 SUBDURAL HAEMATOMA 11 0.0008
520 ORAL HERPES 15 0.0008
521 RETINAL DETACHMENT 7 0.0008
522 BLINDNESS 31 0.0008
523 GASTRITIS 20 0.0008
524 ANOSMIA 11 0.0008
525 BLOOD IRON DECREASED 9 0.0008
526 IRON DEFICIENCY ANAEMIA 7 0.0008
527 FURUNCLE 6 0.0008
528 ABORTION INDUCED 7 0.0007
529 PAIN OF SKIN 20 0.0007
530 NOCTURIA 9 0.0007
531 INSOMNIA 197 0.0007
532 DERMATITIS ATOPIC 39 0.0007
533 HEAD DISCOMFORT 13 0.0007
534 NECK PAIN 41 0.0007
535 PRODUCT USE IN UNAPPROVED INDICATION 181 0.0007
536 LETHARGY 42 0.0007
537 SKIN LESION 20 0.0007
538 UPPER-AIRWAY COUGH SYNDROME 6 0.0007
539 COGNITIVE DISORDER 34 0.0007
540 VENTRICULAR TACHYCARDIA 12 0.0007
541 TOOTH FRACTURE 8 0.0007
542 DIZZINESS POSTURAL 7 0.0007
543 AGEUSIA 18 0.0007
544 SECRETION DISCHARGE 9 0.0007
545 SKIN FISSURES 14 0.0007
546 NEPHROPATHY TOXIC 8 0.0007
547 MUSCLE ATROPHY 9 0.0007
548 LIGAMENT SPRAIN 7 0.0007
549 DISCOMFORT 43 0.0007
550 INTENTIONAL DOSE OMISSION 20 0.0007
551 HYPOTONIA 7 0.0007
552 CONJUNCTIVITIS 13 0.0007
553 PRODUCT CONTAINER ISSUE 6 0.0007
554 MYOCARDITIS 8 0.0007
555 SHOCK 16 0.0007
556 HIATUS HERNIA 9 0.0007
557 RESPIRATORY TRACT CONGESTION 11 0.0007
558 ULCER 11 0.0007
559 DRY THROAT 7 0.0007
560 SUBARACHNOID HAEMORRHAGE 7 0.0007
561 C-REACTIVE PROTEIN INCREASED 25 0.0007
562 JOINT STIFFNESS 18 0.0007
563 SENSORY DISTURBANCE 11 0.0007
564 TEMPERATURE INTOLERANCE 7 0.0007
565 BLINDNESS TRANSIENT 5 0.0007
566 THIRST 12 0.0007
567 JOINT SWELLING 81 0.0007
568 SYNCOPE 67 0.0007
569 DYSPNOEA 379 0.0007
570 RASH ERYTHEMATOUS 32 0.0007
571 THERAPEUTIC RESPONSE UNEXPECTED 30 0.0007
572 ANAL INCONTINENCE 6 0.0007
573 PSORIASIS 87 0.0007
574 RENAL DISORDER 31 0.0007
575 DYSARTHRIA 25 0.0007
576 TACHYPNOEA 9 0.0007
577 ADVERSE EVENT 61 0.0007
578 RENAL PAIN 7 0.0007
579 FUNGAL INFECTION 22 0.0007
580 DYSGEUSIA 49 0.0007
581 OSTEOPENIA 10 0.0007
582 AORTIC ANEURYSM 5 0.0007
583 DISEASE RECURRENCE 31 0.0007
584 UROSEPSIS 6 0.0006
585 INTERVERTEBRAL DISC DEGENERATION 6 0.0006
586 EJECTION FRACTION DECREASED 10 0.0006
587 PRODUCT DISPENSING ERROR 14 0.0006
588 ABDOMINAL DISTENSION 67 0.0006
589 THERAPY PARTIAL RESPONDER 10 0.0006
590 OESOPHAGITIS 7 0.0006
591 FLANK PAIN 6 0.0006
592 MULTI-ORGAN FAILURE 11 0.0006
593 GASTROINTESTINAL PAIN 7 0.0006
594 SEASONAL ALLERGY 9 0.0006
595 DENTAL CARIES 7 0.0006
596 BLOOD ALBUMIN DECREASED 5 0.0006
597 RASH MACULAR 22 0.0006
598 MALNUTRITION 7 0.0006
599 COLD SWEAT 11 0.0006
600 ACUTE RESPIRATORY FAILURE 12 0.0006
601 GLAUCOMA 12 0.0006
602 LOCALISED INFECTION 15 0.0006
603 ERUCTATION 12 0.0006
604 OVERDOSE 133 0.0006
605 THROMBOTIC MICROANGIOPATHY 6 0.0006
606 DECUBITUS ULCER 5 0.0006
607 PHARYNGEAL SWELLING 6 0.0006
608 MICTURITION URGENCY 7 0.0006
609 INTERNAL HAEMORRHAGE 7 0.0006
610 CONVULSION 35 0.0006
611 THERAPY CHANGE 6 0.0006
612 LEUKOCYTOSIS 11 0.0006
613 BONE DISORDER 11 0.0006
614 PAIN IN JAW 17 0.0006
615 COMPLETED SUICIDE 50 0.0006
616 MYALGIA 102 0.0006
617 SLEEP DISORDER 42 0.0006
618 HEMIPARESIS 10 0.0006
619 ANGIOEDEMA 26 0.0006
620 EUPHORIC MOOD 6 0.0006
621 THYROID DISORDER 9 0.0006
622 CORONARY ARTERY OCCLUSION 8 0.0006
623 IRRITABILITY 35 0.0006
624 UNRESPONSIVE TO STIMULI 15 0.0006
625 ANURIA 5 0.0006
626 PROSTATIC SPECIFIC ANTIGEN INCREASED 8 0.0006
627 AGGRESSION 29 0.0006
628 BLOOD MAGNESIUM DECREASED 5 0.0006
629 DIVERTICULITIS 16 0.0006
630 STAPHYLOCOCCAL INFECTION 19 0.0006
631 DEAFNESS 15 0.0006
632 KNEE ARTHROPLASTY 12 0.0006
633 HYPOXIA 20 0.0006
634 FEELING ABNORMAL 136 0.0006
635 TREATMENT NONCOMPLIANCE 31 0.0006
636 OBESITY 9 0.0006
637 VISUAL IMPAIRMENT 70 0.0006
638 CYST 7 0.0006
639 EAR INFECTION 15 0.0006
640 APHASIA 17 0.0006
641 POOR QUALITY SLEEP 12 0.0006
642 DISTURBANCE IN ATTENTION 30 0.0006
643 HAEMATEMESIS 14 0.0006
644 MYOCARDIAL INFARCTION 96 0.0005
645 THROMBOSIS 44 0.0005
646 EMOTIONAL DISTRESS 66 0.0005
647 THERAPEUTIC RESPONSE DECREASED 33 0.0005
648 RESPIRATORY DISTRESS 15 0.0005
649 COAGULOPATHY 9 0.0005
650 PLATELET COUNT INCREASED 7 0.0005
651 LYMPHADENOPATHY 19 0.0005
652 MUSCULAR WEAKNESS 61 0.0005
653 NODULE 7 0.0005
654 POLLAKIURIA 22 0.0005
655 TOXIC EPIDERMAL NECROLYSIS 8 0.0005
656 INJURY 37 0.0005
657 ABASIA 13 0.0005
658 CONFUSIONAL STATE 85 0.0005
659 NEOPLASM 6 0.0005
660 LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES 25 0.0005
661 HYPERHIDROSIS 67 0.0005
662 UPPER RESPIRATORY TRACT INFECTION 24 0.0005
663 ATELECTASIS 5 0.0005
664 PRODUCT TASTE ABNORMAL 7 0.0005
665 PRODUCT DOSE OMISSION ISSUE 152 0.0005
666 RASH PRURITIC 28 0.0005
667 EOSINOPHILIA 9 0.0005
668 AUTOIMMUNE DISORDER 5 0.0005
669 CARDIOVASCULAR DISORDER 13 0.0005
670 SURGERY 30 0.0005
671 CEREBROVASCULAR ACCIDENT 86 0.0005
672 THERAPY CESSATION 26 0.0005
673 BACTERAEMIA 6 0.0005
674 ISCHAEMIC STROKE 9 0.0005
675 NAUSEA 399 0.0005
676 ANAEMIA 96 0.0005
677 PRODUCTIVE COUGH 24 0.0005
678 GASTROINTESTINAL HAEMORRHAGE 42 0.0005
679 ADRENAL INSUFFICIENCY 6 0.0005
680 PRODUCT DOSE OMISSION IN ERROR 14 0.0005
681 MUSCLE TIGHTNESS 8 0.0005
682 FLATULENCE 28 0.0005
683 NEURALGIA 12 0.0005
684 VOMITING 231 0.0005
685 HOT FLUSH 37 0.0005
686 THROAT IRRITATION 22 0.0005
687 PANCREATITIS ACUTE 11 0.0005
688 ASTHENIA 184 0.0005
689 UNEVALUABLE EVENT 37 0.0005
690 DRUG ADMINISTRATION ERROR 15 0.0005
691 BLOOD GLUCOSE ABNORMAL 9 0.0005
692 URINARY TRACT INFECTION 83 0.0005
693 EMOTIONAL DISORDER 15 0.0005
694 COVID-19 85 0.0005
695 FATIGUE 377 0.0005
696 BLOOD ALKALINE PHOSPHATASE INCREASED 12 0.0005
697 FLUSHING 49 0.0005
698 MIDDLE INSOMNIA 9 0.0005
699 THROAT TIGHTNESS 13 0.0005
700 INTENTIONAL PRODUCT MISUSE 42 0.0005
701 RHINORRHOEA 31 0.0005
702 NERVOUSNESS 25 0.0005
703 AMNESIA 31 0.0005
704 TYPE 2 DIABETES MELLITUS 16 0.0005
705 TRANSIENT ISCHAEMIC ATTACK 16 0.0005
706 MOBILITY DECREASED 34 0.0005
707 ABDOMINAL PAIN 110 0.0005
708 COUGH 132 0.0005
709 DRUG EFFECT INCOMPLETE 17 0.0005
710 EPISTAXIS 35 0.0005
711 IMPAIRED WORK ABILITY 10 0.0005
712 DYSPEPSIA 46 0.0005
713 IRRITABLE BOWEL SYNDROME 10 0.0005
714 BLOOD POTASSIUM DECREASED 14 0.0005
715 ANOREXIA 6 0.0005
716 RECTAL HAEMORRHAGE 20 0.0005
717 MUSCULOSKELETAL DISCOMFORT 8 0.0005
718 OROPHARYNGEAL PAIN 43 0.0005
719 ARTHRALGIA 193 0.0005
720 HAEMATOMA 12 0.0005
721 OSTEOPOROSIS 19 0.0005
722 MENTAL DISORDER 20 0.0005
723 BRONCHITIS 34 0.0005
724 LOCAL SWELLING 8 0.0005
725 INSURANCE ISSUE 7 0.0005
726 FEELING HOT 28 0.0005
727 ILLNESS 47 0.0005
728 PULMONARY CONGESTION 6 0.0005
729 PHARYNGEAL OEDEMA 7 0.0005
730 SINUS DISORDER 9 0.0005
731 MELAENA 10 0.0005
732 HYPOGLYCAEMIA 22 0.0005
733 BLOOD TRIGLYCERIDES INCREASED 8 0.0005
734 RESPIRATORY FAILURE 33 0.0005
735 BACK PAIN 105 0.0005
736 LIVER DISORDER 20 0.0005
737 STEVENS-JOHNSON SYNDROME 10 0.0004
738 GENERAL PHYSICAL HEALTH DETERIORATION 52 0.0004
739 STOMATITIS 27 0.0004
740 WEIGHT DECREASED 124 0.0004
741 FEEDING DISORDER 9 0.0004
742 DRY MOUTH 36 0.0004
743 TASTE DISORDER 9 0.0004
744 GASTROENTERITIS VIRAL 8 0.0004
745 CHROMATURIA 10 0.0004
746 HEAD INJURY 14 0.0004
747 CONSTIPATION 96 0.0004
748 CARDIAC ARREST 36 0.0004
749 CARDIAC FAILURE 35 0.0004
750 AGITATION 32 0.0004
751 HIP FRACTURE 14 0.0004
752 RESPIRATORY DISORDER 13 0.0004
753 MUSCLE TWITCHING 10 0.0004
754 FEELING COLD 12 0.0004
755 INTENTIONAL DRUG MISUSE 9 0.0004
756 MASS 6 0.0004
757 BLOOD CHOLESTEROL INCREASED 20 0.0004
758 OXYGEN SATURATION DECREASED 24 0.0004
759 BLOOD TEST ABNORMAL 6 0.0004
760 CHOLELITHIASIS 14 0.0004
761 OSTEOARTHRITIS 18 0.0004
762 RESPIRATORY TRACT INFECTION 11 0.0004
763 SOMNOLENCE 85 0.0004
764 PAIN 259 0.0004
765 BLOOD URINE PRESENT 8 0.0004
766 HAEMORRHAGE 44 0.0004
767 MUSCULOSKELETAL PAIN 22 0.0004
768 CHOLECYSTITIS 5 0.0004
769 CELLULITIS 21 0.0004
770 LOWER LIMB FRACTURE 8 0.0004
771 PARAESTHESIA ORAL 6 0.0004
772 INFECTION 60 0.0004
773 HYPERTHYROIDISM 6 0.0004
774 HERNIA 8 0.0004
775 SINUSITIS 42 0.0004
776 INFLAMMATION 21 0.0004
777 GAMMA-GLUTAMYLTRANSFERASE INCREASED 9 0.0004
778 SKIN HAEMORRHAGE 6 0.0004
779 ABNORMAL WEIGHT GAIN 5 0.0004
780 NIGHTMARE 14 0.0004
781 ACTIVITIES OF DAILY LIVING IMPAIRED 8 0.0004
782 TREMOR 67 0.0004
783 SEPSIS 45 0.0004
784 GASTROINTESTINAL DISORDER 36 0.0004
785 NEUROPATHY PERIPHERAL 38 0.0004
786 PRODUCT SUBSTITUTION ISSUE 23 0.0004
787 AMENORRHOEA 7 0.0004
788 ABDOMINAL PAIN UPPER 82 0.0004
789 HYPOAESTHESIA ORAL 6 0.0004
790 PRODUCT PHYSICAL ISSUE 8 0.0004
791 ASPARTATE AMINOTRANSFERASE INCREASED 21 0.0004
792 HYPOACUSIS 17 0.0004
793 CONTUSION 38 0.0004
794 PRODUCT COMPLAINT 10 0.0004
795 DIARRHOEA 254 0.0004
796 NEPHROLITHIASIS 18 0.0004
797 WHITE BLOOD CELL COUNT INCREASED 15 0.0004
798 ALANINE AMINOTRANSFERASE INCREASED 24 0.0004
799 RIB FRACTURE 8 0.0004
800 MALAISE 170 0.0004
801 ANKLE FRACTURE 6 0.0004
802 OSTEOMYELITIS 7 0.0004
803 INTERNATIONAL NORMALISED RATIO INCREASED 11 0.0004
804 NERVOUS SYSTEM DISORDER 12 0.0004
805 CHILLS 45 0.0004
806 PNEUMONIA 124 0.0004
807 LOSS OF CONSCIOUSNESS 49 0.0004
808 MUSCLE SPASMS 70 0.0004
809 DIABETES MELLITUS 29 0.0004
810 HAEMATURIA 13 0.0004
811 ABSCESS 6 0.0004
812 HYPOTHYROIDISM 12 0.0004
813 EATING DISORDER 8 0.0004
814 PSYCHOTIC DISORDER 11 0.0004
815 LACTIC ACIDOSIS 12 0.0004
816 DECREASED APPETITE 86 0.0004
817 HYPOCALCAEMIA 7 0.0004
818 FAECES DISCOLOURED 8 0.0004
819 GASTRIC ULCER 7 0.0004
820 PRODUCT PRESCRIBING ISSUE 8 0.0004
821 INJECTION SITE URTICARIA 9 0.0004
822 INCREASED APPETITE 7 0.0004
823 MULTIPLE FRACTURES 6 0.0004
824 EYE DISORDER 12 0.0004
825 DRUG PRESCRIBING ERROR 7 0.0004
826 MEMORY IMPAIRMENT 50 0.0004
827 CEREBRAL HAEMORRHAGE 13 0.0004
828 RESPIRATORY ARREST 10 0.0004
829 VIRAL INFECTION 12 0.0004
830 DYSPHONIA 21 0.0004
831 BONE PAIN 21 0.0004
832 WOUND 10 0.0004
833 CARPAL TUNNEL SYNDROME 5 0.0004
834 THERAPY NON-RESPONDER 16 0.0004
835 ABDOMINAL PAIN LOWER 9 0.0004
836 BLINDNESS UNILATERAL 5 0.0004
837 DISORIENTATION 14 0.0004
838 CATARACT 21 0.0004
839 DEHYDRATION 47 0.0004
840 HEPATIC ENZYME INCREASED 24 0.0004
841 PAIN IN EXTREMITY 103 0.0003
842 CARDIOGENIC SHOCK 5 0.0003
843 GAIT DISTURBANCE 66 0.0003
844 BODY TEMPERATURE INCREASED 7 0.0003
845 MUSCULOSKELETAL STIFFNESS 30 0.0003
846 ARTHROPATHY 19 0.0003
847 WHITE BLOOD CELL COUNT DECREASED 37 0.0003
848 PANCYTOPENIA 19 0.0003
849 HOSPITALISATION 52 0.0003
850 TOOTH LOSS 7 0.0003
851 JAUNDICE 9 0.0003
852 BLOOD GLUCOSE DECREASED 16 0.0003
853 HALLUCINATION, VISUAL 7 0.0003
854 VISUAL ACUITY REDUCED 11 0.0003
855 ARTHRITIS 26 0.0003
856 JOINT INJURY 7 0.0003
857 ASTHMA 37 0.0003
858 INJECTION SITE RASH 10 0.0003
859 ANGER 11 0.0003
860 HYPOKALAEMIA 15 0.0003
861 BALANCE DISORDER 28 0.0003
862 LIMB DISCOMFORT 10 0.0003
863 ALTERED STATE OF CONSCIOUSNESS 7 0.0003
864 ABDOMINAL DISCOMFORT 54 0.0003
865 BACTERIAL INFECTION 6 0.0003
866 INTERVERTEBRAL DISC PROTRUSION 7 0.0003
867 INTESTINAL OBSTRUCTION 12 0.0003
868 CYSTITIS 10 0.0003
869 HYPERSOMNIA 9 0.0003
870 INJECTION SITE PRURITUS 21 0.0003
871 GLOSSODYNIA 7 0.0003
872 HEPATITIS 8 0.0003
873 PYREXIA 108 0.0003
874 DRUG INTERACTION 49 0.0003
875 PHARMACEUTICAL PRODUCT COMPLAINT 8 0.0003
876 CHOKING 6 0.0003
877 PRODUCT AVAILABILITY ISSUE 7 0.0003
878 LUNG DISORDER 15 0.0003
879 KIDNEY INFECTION 6 0.0003
880 PULMONARY EMBOLISM 29 0.0003
881 WRONG TECHNIQUE IN DRUG USAGE PROCESS 11 0.0003
882 PANCREATITIS 16 0.0003
883 INJECTION SITE BRUISING 24 0.0003
884 INJECTION SITE SWELLING 23 0.0003
885 URINARY RETENTION 10 0.0003
886 HEPATIC FAILURE 9 0.0003
887 FREQUENT BOWEL MOVEMENTS 8 0.0003
888 CANDIDA INFECTION 5 0.0003
889 THERAPY INTERRUPTED 21 0.0003
890 DIABETIC KETOACIDOSIS 7 0.0003
891 TREATMENT FAILURE 24 0.0003
892 PROCEDURAL PAIN 8 0.0003
893 RHABDOMYOLYSIS 12 0.0003
894 WHEEZING 17 0.0003
895 DEMENTIA 8 0.0003
896 DEVICE USE ISSUE 5 0.0003
897 WITHDRAWAL SYNDROME 12 0.0003
898 ENCEPHALOPATHY 7 0.0003
899 DYSPHAGIA 27 0.0003
900 SYSTEMIC LUPUS ERYTHEMATOSUS 10 0.0003
901 BLOOD GLUCOSE INCREASED 53 0.0003
902 PRODUCT ADHESION ISSUE 10 0.0003
903 FALL 92 0.0003
904 HYPERGLYCAEMIA 10 0.0003
905 TOXICITY TO VARIOUS AGENTS 46 0.0003
906 DRUG RESISTANCE 7 0.0003
907 PSORIATIC ARTHROPATHY 11 0.0003
908 DYSKINESIA 11 0.0003
909 URINARY INCONTINENCE 8 0.0003
910 TRANSAMINASES INCREASED 6 0.0003
911 TOOTH DISORDER 6 0.0003
912 COLITIS 10 0.0003
913 ROAD TRAFFIC ACCIDENT 11 0.0003
914 NASOPHARYNGITIS 48 0.0003
915 NEOPLASM MALIGNANT 17 0.0003
916 DISABILITY 5 0.0003
917 DEPRESSED LEVEL OF CONSCIOUSNESS 10 0.0003
918 COMA 12 0.0003
919 INFLUENZA 28 0.0003
920 THROMBOCYTOPENIA 28 0.0003
921 INJECTION SITE ERYTHEMA 31 0.0002
922 CHRONIC OBSTRUCTIVE PULMONARY DISEASE 13 0.0002
923 HYPONATRAEMIA 14 0.0002
924 MULTIPLE ORGAN DYSFUNCTION SYNDROME 7 0.0002
925 COLITIS ULCERATIVE 11 0.0002
926 LIVER INJURY 6 0.0002
927 IMPAIRED HEALING 8 0.0002
928 BLOOD CREATINE PHOSPHOKINASE INCREASED 7 0.0002
929 THERAPEUTIC RESPONSE SHORTENED 8 0.0002
930 PNEUMONIA ASPIRATION 6 0.0002
931 GAIT INABILITY 8 0.0002
932 PRODUCT QUALITY ISSUE 32 0.0002
933 HAEMATOCHEZIA 13 0.0002
934 PLATELET COUNT DECREASED 25 0.0002
935 RASH GENERALISED 6 0.0002
936 HEART RATE DECREASED 8 0.0002
937 HERPES ZOSTER 13 0.0002
938 FEMUR FRACTURE 7 0.0002
939 LIMB INJURY 6 0.0002
940 PALLOR 6 0.0002
941 CRYING 8 0.0002
942 INJECTION SITE PAIN 66 0.0002
943 HAEMOPTYSIS 6 0.0002
944 SEPTIC SHOCK 9 0.0002
945 DYSSTASIA 6 0.0002
946 GASTRIC DISORDER 7 0.0002
947 DISEASE PROGRESSION 24 0.0002
948 ABNORMAL BEHAVIOUR 8 0.0002
949 NEOPLASM PROGRESSION 7 0.0002
950 HALLUCINATION 15 0.0002
951 EPILEPSY 6 0.0002
952 BONE DENSITY DECREASED 6 0.0002
953 BLOOD BILIRUBIN INCREASED 5 0.0002
954 DEEP VEIN THROMBOSIS 12 0.0002
955 VAGINAL HAEMORRHAGE 8 0.0002
956 PRODUCT STORAGE ERROR 16 0.0002
957 DEVICE DELIVERY SYSTEM ISSUE 5 0.0002
958 INFLUENZA LIKE ILLNESS 15 0.0002
959 SEIZURE 21 0.0002
960 LEUKOPENIA 9 0.0002
961 WRONG TECHNIQUE IN DEVICE USAGE PROCESS 8 0.0002
962 INCORRECT ROUTE OF DRUG ADMINISTRATION 6 0.0002
963 ELECTROCARDIOGRAM QT PROLONGED 6 0.0002
964 INFUSION RELATED REACTION 11 0.0002
965 INTERSTITIAL LUNG DISEASE 8 0.0002
966 DRUG DOSE OMISSION 27 0.0002
967 HEPATIC FUNCTION ABNORMAL 6 0.0002
968 DRUG WITHDRAWAL SYNDROME 14 0.0002
969 PRODUCT DOSE OMISSION 10 0.0002
970 INJECTION SITE HAEMORRHAGE 12 0.0002
971 DRUG EXPOSURE DURING PREGNANCY 5 0.0001
972 RENAL CANCER 7 0.0001
973 DRUG INTOLERANCE 14 0.0001
974 DELIRIUM 5 0.0001
975 DEVICE USE ERROR 5 0.0001
976 NEUTROPENIA 19 0.0001
977 FOETAL EXPOSURE DURING PREGNANCY 11 0.0001
978 DEATH 115 0.0001
979 MATERNAL EXPOSURE DURING PREGNANCY 11 0.0001
980 DEVICE ISSUE 11 0.0001
981 MALIGNANT NEOPLASM PROGRESSION 12 0.0001
982 RHEUMATOID ARTHRITIS 13 0.0001
983 PROSTATE CANCER 9 0.0001
984 DEVICE MALFUNCTION 7 0.0001
985 ILL-DEFINED DISORDER 6 0.0001
986 BREAST CANCER 9 0.0001
987 ANAPHYLACTIC REACTION 5 0.0001
988 FEBRILE NEUTROPENIA 6 0.0001
989 INJECTION SITE REACTION 6 0.0001
990 DRUG ABUSE 6 0.0001
991 DRUG DOSE OMISSION BY DEVICE 5 0.0001